Find Clinical Trial

A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of the Liquid and the Lyophilized Formulations of Pegaspargase (S95014) in Treatment of Paediatric Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

← Back
Study Phase

Phase 2

Therapeutic Area


IndicationAcute Lymphoblastic Leukemia
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device


Active Substance CodeS095014
Protocol CodeCL2-95014-002
EudraCT Code 2020-004894-29
NCT CodeNCT04954326

Documents and links

Lay summary
Results summary READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.